Only 20-25 MS reps left in select markets???

Discussion in 'Novartis' started by Anonymous, Aug 3, 2014 at 12:59 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    This is ridiculous! Why is NVS cutting over 80 percent of MSBU reps in November? Voice of share is low vs Tec as it is! Big mistake NVS!
     

  2. Anonymous

    Anonymous Guest

    SAMS a complete failure. Will be demoted not released. No 2 reps in territory. Territories consolidated. Just more travel for some.

    Why? 10% market share. Launch is over. No need for the amount of reps. PPMS indication will sell itself to MS KOLS IF GETS APPROVED. All other drugs submitted for approval for PPMS failed.
     
  3. Anonymous

    Anonymous Guest

    Actually someone from HQ said thst 100 percent of reps gone after November. It will all be KAMs to talk to KOLs and NGNs. Reps get zero access and provide only a drain. Let's increase profits!
     
  4. Anonymous

    Anonymous Guest

    I would nt call it zero access. No doctor wants a rep around 2 or 3 times per week with the same product.
     
  5. Anonymous

    Anonymous Guest

    Docs don't want us around at all
     
  6. Anonymous

    Anonymous Guest

    Same thing will happen to derm in 3 years
     
  7. Anonymous

    Anonymous Guest

    You call Biogen beating you silly a good thing? Gilenya is not even in the game. Total wannabe.
     
  8. Anonymous

    Anonymous Guest

    Anyone who thinks just because Gilenya is a billion dollar product it is successful doesn't understand the MS environment.

    Basel expected at least a 25% market share at 4 years. Not even close. Everyone from Dagmar to the micro management bald ABLs know the heat is on. Changes occur when the heat is on.
     
  9. Anonymous

    Anonymous Guest

    All the orals COMBINED do not have 25 percent market share you moron
     
  10. Anonymous

    Anonymous Guest

    Last IMS report I saw

    Tec 16.3%
    Gil 9.7%
    Aub 6.9%

    Tec and Aub exceeding expectations
     
  11. Anonymous

    Anonymous Guest

    This report does not include Tysabri dumb ass! No wonder MSBU is in trouble. You don't even understand the market you are playing in!
     
  12. Anonymous

    Anonymous Guest

    So Gilenya is much less then 10%? Are you thinking 6% market share? Better inform leadership

    That's right. Gilenya is doing great. It is beating Tecfidera, it is selling $3 billion annually but we wont tell anyone, Neurologists love it, the leadership in the MSBU is loved and are doing a great job, macro-management at its best, management by trust not fear, reps get up in the morning with a smile on their face because they love the MSBU, no side effects, no patient complaints, easy to start a patient, no employee turnover, great bonuses.

    WOW - The MSBU is the place to be!!!!!
     
  13. Anonymous

    Anonymous Guest

    Not since analysis has shown that we got here with little or no contribution from the sales force. That's why we are all mostly gone.
     
  14. Anonymous

    Anonymous Guest

    I know mgmt is what keeps us afloat. Dreamy situation.
     
  15. Anonymous

    Anonymous Guest

    The micro management skills of the ugly bald ABL has made Gilenya a Billion dollar product
     
  16. Anonymous

    Anonymous Guest

    Conrad? Useless drone who can't sell or motivate to save his live.
     
  17. Anonymous

    Anonymous Guest

    C rad still around? What he doing these days?
     
  18. Anonymous

    Anonymous Guest

    Well, we will get to see won't we? Since, your shot is about to be in the street.
     
  19. Anonymous

    Anonymous Guest

    Does someone have the $ Dollar amount $ paid by Novartis to MS KOL's?
    & how large a % of scripts come from those paid KOL's?
    I suspect pro publica does
     
  20. Anonymous

    Anonymous Guest


    Dumba**. Thats all public record now. Look it up yourself and get off this site if you dont work here.